logo

For the Inventor, By the Inventor

Heidelberg, Germany

Andreas G Niethammer

This inventor holds 3 USPTO granted patents. Top assignee: Scripps Research Institute. Active years: 2006-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andreas G Niethammer. Retrieved from https://idiyas.com/inventor/andreas-g-niethammer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3

% Patents Active = 66.7

Average Co-Inventor Count = 3.0

ph-index = 2

Forward Citations = 16(Granted Patents)


Location History:

  • San Diego, CA (US) (2006)
  • Heidelberg, DE (2011 - 2012)

Company Filing History:

goldMedal3 out of 1,206 
 
Scripps Research Institute
 patents

Years Active: 2006-2012

Loading Chart...
3 patents (USPTO):Explore Patents
1. 8241637 - DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof (2012-08-14),
2. 8048428 - DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof (2011-11-01),
3. 7094410 - DNA vaccine against proliferating endothelial cells and methods of use thereof (2006-08-22),

Title: Innovations of Andreas G Niethammer

Introduction

Andreas G Niethammer is a notable inventor based in Heidelberg, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of DNA compositions that target vascular endothelial growth factor (VEGF) receptors. His work has implications for cancer treatment, specifically in inhibiting tumor growth.

Latest Patents

Niethammer holds 3 patents related to his innovative research. His latest patents include a DNA composition encoding an immunogenic VEGF receptor peptide and methods of use thereof. This invention provides a method for inhibiting endothelial cell proliferation in mammals by administering a DNA composition that encodes a VEGF receptor polypeptide. The method aims to elicit an immune response that targets proliferating endothelial cells, thereby inhibiting angiogenesis and reducing tumor growth and dissemination.

Career Highlights

Niethammer is affiliated with The Scripps Research Institute, where he continues to advance his research in immunology and cancer therapy. His work has garnered attention for its potential to improve therapeutic strategies against tumors by targeting the tumor micro-environment.

Collaborations

Some of his notable coworkers include Ralph A Reisfeld and Rong Xiang. Their collaborative efforts contribute to the ongoing research and development in the field of cancer immunotherapy.

Conclusion

Andreas G Niethammer's innovative work in the field of biotechnology highlights the importance of targeted therapies in cancer treatment. His patents and research continue to pave the way for advancements in medical science.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…